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Abstract
Background: A significant number of the population is on 3-hydroxy-3methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors (statins) because statins are the main pharmacologic drug prescribed for the
treatment of hypercholesteremia. Statins also have been shown to reduce the relative risks of coronary events.
Statins work by inhibiting the mevalonate pathway. This is the same pathway from which Coenzyme Q10 is
synthesized. Coenzyme Q10 is essential for muscle respiration. One of the theories is that statin therapy
reduces coenzyme Q10 levels in muscle mitochondria, which leads to myalgia. One of the primary side effects
of statin drugs is myalgia which often causes patients to decrease the dosage of the statin or discontinue it. The
clinical question of whether coenzyme Q10 can be used in the treatment of myopathic pain caused by statin
drug use is a common one encountered by health care providers in primary care. This article is a review of the
literature to further address this question.
Methods: A systematic review of the English-language published literature was conducted using MEDLINE,
CINAHL and ISI Web of Science using keywords myalgia, muscle pain, myopathy, statin, HMG-CoA,
reductase inhibitors, Coenzyme Q10, CoQ10, and ubiquinone. There is very limited research examining the
outcome of Coenzyme Q10 for the treatment of myopathy in statin users. Two randomized control studies
researching this outcome and one prospective cohort study were retrieved and analyzed for quality and
results.
Results: One randomized control study found a significant relationship between the use of Coenzyme Q10
and a decrease in myopathic symptoms, as did the prospective cohort study. However, the other randomized
control study found no clinical significance in decreased myopathic symptoms with the addition of Coenzyme
Q10. Fewer results were of statistical or clinical significance after the adjustments for known confounders
were completed. Limited results showed Coenzyme Q10 supplementation decreased myopathic symptoms in
patients on statin medications.
Conclusion: Current guidelines suggest placing patients on the lowest dose of statin medication to control the
cholesterol and to decrease side effects like myopathy. Additional randomized trials of larger populations are
needed to quantify and qualify possible risks of Coenzyme Q10 supplementation using myopathy as an
independent risk factor.
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Abstract   
 
Background:  A significant number of the population is on 3-hydroxy-3methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors (statins) because statins are the main 
pharmacologic drug prescribed for the treatment of hypercholesteremia. Statins also have 
been shown to reduce the relative risks of coronary events. Statins work by inhibiting the 
mevalonate pathway. This is the same pathway from which Coenzyme Q10 is 
synthesized. Coenzyme Q10 is essential for muscle respiration. One of the theories is that 
statin therapy reduces coenzyme Q10 levels in muscle mitochondria, which leads to 
myalgia. One of the primary side effects of statin drugs is myalgia which often causes 
patients to decrease the dosage of the statin or discontinue it. The clinical question of 
whether coenzyme Q10 can be used in the treatment of myopathic pain caused by statin 
drug use is a common one encountered by health care providers in primary care. This 
article is a review of the literature to further address this question.  
Methods:  A systematic review of the English-language published literature was 
conducted using MEDLINE, CINAHL and ISI Web of Science using keywords myalgia, 
muscle pain,  myopathy, statin, HMG-CoA, reductase inhibitors, Coenzyme Q10, 
CoQ10,  and ubiquinone. There is very limited research examining the outcome of 
Coenzyme Q10 for the treatment of myopathy in statin users. Two randomized control 
studies researching this outcome and one prospective cohort study were retrieved and 
analyzed for quality and results.  
Results:  One randomized control study found a significant relationship between the use 
of Coenzyme Q10 and a decrease in myopathic symptoms, as did the prospective cohort 
study. However, the other randomized control study found no clinical significance in 
decreased myopathic symptoms with the addition of Coenzyme Q10. Fewer results were 
of statistical or clinical significance after the adjustments for known confounders were 
completed. Limited results showed Coenzyme Q10 supplementation decreased 
myopathic symptoms in patients on statin medications. 
Conclusion:  Current guidelines suggest placing patients on the lowest dose of statin 
medication to control the cholesterol and to decrease side effects like myopathy. 
Additional randomized trials of larger populations are needed to quantify and qualify 
possible risks of Coenzyme Q10 supplementation using myopathy as an independent risk 
factor.  
Keywords:  myalgia, HMG-CoA, reductase inhibitors, Coenzyme Q10 
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Coenzyme Q10 Supplementation for the Treatment of Statin 
Induced Myalgia 
 
BACKGROUND 
Overview 
 
A significant number of health care patient population is currently on 3-hydroxy-
3methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). Statins have 
been shown to reduce the relative risks of coronary events and decrease mortality.2 
Current guidelines also recommend statins as first line therapy for reducing low-density 
lipoprotein cholesterol (LDL-C).2 Despite this, adherence to lipid-lowering treatments 
with statin medication decreases due to the side effects. Because hypercholesterolemia is 
largely asymptomatic, any unpleasant side effects of pharmacologic agents, such as 
statins, can decrease  compliance .3  
Myalgia is one of the most frequently reported adverse side affects associated 
with statin therapy.4 In two large observational studies, 10-15% of patients had 
complaints of myopathy .5,6 Muscle symptoms usually occur within the first six months 
of therapy, although they can begin months to years after initiation of treatment.7 
Radcliffe et al8 addresses the difficulty of defining statin myalgia as it is often 
inaccurately and inconsistently used throughout the literature. Myalgia is a subjectively 
reported sensation of muscle pain .8 Jacobson et al7 furthered the description of myalgia 
describing that it manifests as heaviness, stiffness, cramping or weakness that may be 
persistent, intermittent or occur only during exertion without creatine kinase (CK) 
elevation. Sometimes this pain can become so severe that it interferes with a patient’s 
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activities of daily living leading to a reduction in their statin use. Myopathy refers to 
muscle symptoms with CK elevation, while rhabdomyolysis refers to CK elevations 
greater than 10,000U/L, usually with renal compromise and urinary myoglobin.9 Both 
myopathy and rhabdomyolysis are rare side effects. For the purpose of this paper, 
myalgia and myopathic pain were identified and measured as the outcome. 
There are many identified and well researched risk factors for statin myopathy. 
The PRIOMO study5 indicated that patients were at a significantly elevated risk of statin 
myalgia if they had a personal or family history of this side effect while using lipid-
modifying therapy. CK elevation, hypothyroidism, decreased renal and hepatic function 
also were associated with an increased risk for statin induced myopathy.5  Law et al10 also 
noted advancing age, small body size, female sex and race/ethnicity, especially in Asians 
due to decreased clearance of the drug, all had associated risk factors for increased 
occurrence of myalgia. Therefore, when prescribing statin medications these confounding 
variables must be assessed and discussed with the patient, while encouraging them to 
report any such side effects. 
Statins work by inhibiting HMG-CoA reductase and the mevalonate pathway.11 
Coenzyme Q10 (CoQ10) or ubiquinone is synthesized from mevalonate and tyrosine and 
is one of several products of the mevalonate pathways .12 HMG-CoA reductase inhibitors, 
or statins, block the production of mevalonate from HMG-CoA (see Figure 1). 
Mevalonate is used to synthesize cholesterol as well as CoQ10. 13 Therefore, statin drugs 
work by interfering with this pathway, lowering cholesterol and simultaneously lowering 
CoQ10 levels. There has been extensive evidence that shows that statins lower serum 
CoQ1- levels.1,11,14-17 A key component of the mitochondrial respiratory chain is 
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CoQ10.18 It participates in electron transport during oxidative phosphorylation in the 
mitochondria of muscle cells.13 Accordingly, one of the proposed theories for the cause 
of myopathy in statin drug users is that CoQ10 deficiency resulting from statin treatment 
may impair muscle energy metabolism and contribute to the development of myopathy in 
patients treated with statins.19, 20 Oral supplementation with CoQ10 has been shown to 
reverse the decrease in serum CoQ10 levels by statins.11,15,16 In an open label phase I trial 
in cancer patients Thibault et al15 evaluated the effect of very high doses of lovastatin (up 
to 35mg/kg) with or without CoQ10 supplementation 240mg/day. CoQ10 
supplementation did not decrease the incidence of musculoskeletal toxicity, however, it 
did significantly reduce its severity. This study was aimed at the prevention of myopathic 
pain rather than the treatment of patients already with myopathic pain on statin 
medications, but it was one of the first to address the theory of coenzyme Q10 
supplementation as it correlates to statin myopathy.  
Purpose of Study  
This systematic review examines original research that contributes to the 
understanding of the supplementation of coenzyme Q10 for the treatment of statin 
myopathy or myalgia. The question of whether coenzyme Q10 supplementation prevents 
myalgia and myopathic pain caused by statins is one commonly encountered in primary 
care. Health care providers who search for evidence based literature and guidelines find 
little research that address this question directly. Current recommendations for the 
management of statin myotoxicity are to obtain a baseline serum CK level prior to 
initiating statin therapy. Measuring follow-up serum CK levels is not recommended 
unless the patient develops signs or symptoms of myotoxicity which includes myalgia.21 
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The American College of Cardiology, American Heart Association and the National 
Heart, Lung and Blood Institute recommend following the CK level weekly in a patient 
with muscle soreness or pain.22 If CK exceeds 10x ULN at any time, prompt 
discontinuation of the statin is indicated.22 Consideration should be given to treatment 
with coenzyme Q10,60 miligrams (mg) twice daily for two months. 1,23 
 Because of the vast population prescribed and taking statin medications and 
because of the frequency of myalgia that is reported, it is imperative to remain abreast of 
the information that is relevant to this question.  
 
METHODS 
Search Strategy 
 In order to gather all of the most pertinent articles related to the chosen topic, a 
systematic review of the English-language published literature was conducted using 
MEDLINE, CINAHL and ISI Web of Science using keywords myopathy, muscle pain, 
myalgia, statin, HMG-CoA, reductase inhibitors, Coenzyme Q10, CoQ10, and 
ubiquinone. These terms were searched separately as keywords, then combined to form a 
single search using the “and” command. The extensive online search produced 
approximately 90 articles that met the combination of at least three of the search words 
used over the three search engines. This included overlap that produced the same articles 
on different search engines. Subsequent examination of bibliographic entries in retrieved 
works yielded additional background information. A total of 28 articles were used in this 
systematic review.  
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Inclusion/Exclusion Criteria 
The search was limited to English language, human population and adult subjects. 
Studies with a focus on coenzyme Q10 and improvement of endothelial dysfunction, the 
measurement of CoQ10 levels in plasma or muscle tissues, or the effects of CoQ10 in 
heart failure, hypertension, diabetes, malignancy and Parkinson’s disease were all 
excluded. After narrowing the search as described, articles were further investigated and 
excluded if they did not directly address the correlation of coenzyme Q10 
supplementation in the treatment of myalgia of patients who were taking statin 
medication.  
The Jadad score, which is a commonly used set of criteria to assess the validity of 
articles, could not be applied here because the studies analyzed were not all randomized 
control trials. Therefore, it became necessary to create an original validity grading scale 
to more formally assess the group of articles included in the systematic analysis. Using 
this unique method (see Table 1) a relative score representing quality, validity and 
reliability in relation to the clinical question was assigned to each article. Each article was 
given a numeric score according to this set of criteria. This score, ranging from 0-8, was 
used to represent how much weight should be given to the article in supporting the 
hypothesis of the clinical question. No studies were eliminated from the review by this 
score.  
 
RESULTS 
Because there is very limited research examining the outcome of Coenzyme Q10 
for the treatment of myopathy in statin users, two randomized control studies researching 
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this outcome and one prospective cohort study were retrieved and analyzed for quality 
and results (see Table 2).   
Caso et al1 were the first to publish a clinical pilot study to test whether 
supplementation with coenzyme Q10 would improve muscle symptoms in patients using 
statins. In this study, Effect of Coenzyme Q10 on Myopathic Symptoms in Patients 
Treated with Statins, Caso et al1 enrolled 32 patients who were being treated for 
hyperlipidemia with a HMG-CoA reductase inhibitor (statin) and had reported myopathic 
symptoms.  Eighteen subjects were randomized to the CoQ10 group, while 14 were 
randomized to the Vitamin E control group. Patients were enrolled only if there were no 
other identifiable cause of myopathy. Subjects with cofounding variables of hepatic, 
vascular, renal, endocrine or coagulopathy disease were also excluded. None of the 
patients enrolled had previously been using coenzyme Q10 or vitamin E before.  Caso et 
al1 stated, “that there were no differences in statin treatment between groups.”  There 
were 11 subjects using simvastatin both in the CoQ10 group and the control group. Three 
subjects were on atorvastatin in the control group, while four were on atorvastatin in the 
CoQ10 group. The CoQ10 group also had two patients using pravastatin and one patient 
on lovastatin. Five subjects in the CoQ10 and four in the vitamin E control group were 
using medications with analgesic properties prior to and during the intervention period. 
Both groups were similar for age, weight, height and body mass index. Coenzyme Q10 or 
vitamin E were supplemented for 30 days, 100mg and 400IU consecutively. Vitamin E 
was chosen as the placebo for the control group to control for the antioxidant actions of 
coenzyme Q10 and because both supplements were similar in appearance.1 
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In addition to measuring plasma concentrations of CK and fasting lipids, this 
controlled, double-blind randomized trial1 evaluated myopathic pain before and after 
treatment with coenzyme Q10 or vitamin E using the Brief Pain Inventory questionnaire. 
The Brief Pain Inventory measures pain intensity on a 0-10 scale (i.e, 0=no pain and 10= 
pain as bad as you can imagine). This tool was also used to measure pain interference 
with daily life on 7 different items (i.e. general activity, mood, walking, working,  
relations with others, sleeping and enjoyment of life) on a scale of 0-10. Caso et al1 
calculated a Pain Interference Score (PIS) by obtaining average ratings of the 7 
interference items. The data were reported as a mean +/- SEM (standard error of the 
mean). They made comparisons of measurements before and after intervention within the 
same group using a t-test for paired data. They also made comparisons between the 
coenzyme Q10 and control treatment groups using a t-test. The authors reported that 
compliance with either supplement was 100% in both groups.1  
Caso et al1 found that plasma cholesterol, LDL cholesterol and triglycerides were 
similar in both groups before starting the intervention and did not change over the month 
study period. The authors found that intensity of myopathic pain (PSS) was similar in the 
conenzyme Q10 group and vitamin E groups before supplementation as was the 
interference of pain with daily living activities (PIS). The p value for both measurements 
was >0.05 and were not considered to be significant. No change in pain intensity was 
observed in the control group using vitamin E supplementation at the end of the trial. 
However, the change in PSS after the month long intervention with Coenzyme Q10 was 
significantly different (p=<0.001). In the Coenzyme Q10 group, 16 of 18 patients 
reported a decrease in their myopathic pain, while only 3 of 14 reported pain relief with 
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placebo vitamin E. Caso et al1 reported that interference of pain decrease with daily 
activities significantly improved by 38% +/- 14% in patients using coenzyme Q10 
(p<0.02). The vitamin E control group did not report a significant reduction in pain 
interference with daily activities.1     
Based on the results of this pilot study, Caso et al1 suggested that coenzyme Q10 
may be beneficial for patients using statins by lessening myopathic symptoms and 
improving patients ability to perform activities of daily living. A 40% decrease in muscle 
pain with Coenzyme Q10 and a 38% improvement of interference with pain during their 
daily life activities was also described. The authors went on to state there may be a 
possible etiologic role of coenzyme Q10 depletion in the pathogenesis of myopathic 
symptoms in statin-treated patients, supporting the hypothesis that myopathic pain in 
patients treated with statins is a result of the inability of the mitochondria to supply the 
ATP (Adenosine-5'-triphosphate) needed for muscle contraction secondary to decreased 
coenzyme Q10 levels.1  
Young et al17 conducted a randomized trial to examine the impact of coenzyme 
Q10 supplementation on statin-induced myalgia. Effect of Coenzyme Q10 
Supplementation on Simvastatin-Induced Myalgia was a double-blind, placebo-controlled 
pilot study that enrolled 44 patients with self-reported myalgia who had been unable to 
continue taking adequate doses of statin therapy secondary to this side effect. Patients 
who had a history of acute myocardial infarction or cerebral vascular accident within 
three months, alanine aminotransferase or aspartate aminotransferase >3 times the upper 
level of normal, a calculated glomerular filtration rate <45 ml/min, decompensated heart 
failure, warfarin treatment or antioxidant vitamin supplementation were excluded from 
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the study to control for confounding variables. Prior to randomization, patients underwent 
a two week washout of conenzyme Q10-supplements and lipid modifying therapies 
except ezetimibe (n=4).17 
 Patients in this study were stratified according to the severity of previous myalgic 
symptoms either as severe or moderate. Young et al17 described severe myalgia as the 
inability to tolerate a statin dose of 20-40 mg/day within 1 month of commencement and 
moderate myalgia as development of symptoms at doses >20 mg/day after >1month. 
Patients were then further randomized within each severity of myalgia to treatment with 
coenzyme Q10 (200mg/d) or placebo for 12 weeks in combination with simvastatin. The 
simvastatin therapy was titrated up from a starting dose of 10-20mg/day and then to 
40mg/day at 4 week intervals. During each visit, throughout the intervention, fasting 
blood samples were taken that measured total plasma coenzyme Q10, total cholesterol, 
triglycerides, high-density lipoprotein cholesterol, creatine kinase electrolytes, renal and 
liver function and a full blood count. The study17 also measured whole-blood lactate and 
pyruvate concentrations. Myalgia was assessed daily during the study using a visual 
analogue scale rating the intensity of pain from 0-100mm that the authors adapted from 
Landstad et al.24 Using this scale, patients documented the number of sites affected by 
myalgia and rated the intensity of pain. Patients who experienced significant myalgia 
reduced their simvastatin dose or discontinued the study medication if they could not 
tolerate the lowest dose of simvistatin (10mg/d). The study looked at the primary 
outcomes of the number of patients who tolerated simvastatin 40mg/day at 12 weeks, the 
number of patients who remained on simvastatin therapy and the change in the myalgia 
score.17 
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 The results of this study17 showed that there were no significant differences 
observed between the coenzyme Q10 group and the placebo group in the number of 
patients who tolerated the simvastatin 40mg/d or in the number of patients who remained 
on simvastatin at any dose. This was also true when each group was stratified according 
to the severity of previous statin-induced myalgia. The authors also found there to be no 
differences between the two groups in the change in myalgia score. Therefore, Young et 
al17 felt that they could not demonstrate any significant beneficial effect of coenzyme 
Q10 supplementation on myalgic symptoms in patients with histories of statin-related 
myalgia.  
Langsjoen et al25 chose to supplement 50 patients who were experiencing one or 
more statin drug side effects, including myalgia, with 240mg on an average of coenzyme 
Q10 daily and to discontinue statin medication simultaneously in his study Treatment of 
Statin Adverse Effects with Supplemental Coenzyme Q10. This was a prospective analysis 
of a subset of 50 new cardiology clinic patients who were actively taking statin drug 
therapy during their initial visit. The authors chose to evaluate patients for five possible 
categories of statin adverse effects including myalgia with or without muscle weakness. 
For the purpose of this systematic review, only the outcome of myalgia will be discussed, 
although fatigue, dyspnea, memory loss and peripheral neuropathy were also analyzed 
within the study. Initial and follow-up echocardiograms that measured left ventricular 
size and function was conducted on 28 of 50 patients enrolled. The majority of patients 
enrolled in the study were on Lipitor or Zocor and on average patients had been using 
their statin for approximately two years. Sixty-four percent of patients enrolled in the 
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study complained of myalgia with and without proximal muscle weakness at the 
beginning of the study.25 
Langsjoen et al25 found that fatigue and myalgia were beginning to improve by one 
month follow-up and significantly by three month follow-up, with myalgia decreasing 
from 64% to 6% overall.  
 
DISCUSSION 
Study Limitations 
 Much has been written on statins and myopathy and the possible role of CoQ10. 
The theory that statins cause depletion of CoQ10 in muscles is plausible as statins block 
the production of mevalonate, one of the precursors of CoQ10.13 These articles are the 
few that begin to speak to the question of coenzyme Q10 supplementation for the 
treatment of statin induced myalgia. This body of work reflects a small variety of 
research methods and their results are of inconsistent quality. When taken together, the 
two conducted randomized control trial and the prospective cohort study failed to provide 
a clear answer to the issue. Although two of the studies reported a reduction in statin 
induced myopathic pain, their results are imperfect secondary to the limitations of the 
study design.1,25  
Caso et al1 was restricted by the lack of placebo control design. While the use of 
Vitamin E as a placebo was explained, Vitamin E has its own effects on the body’s 
system and may have affected the measured outcome of myopathic pain. This study1 was 
also limited by its small study population. Despite the fact that this study was identified 
as a pilot study, the failure to standardize the dose and type of statin treatment may also 
18 
 
have affected the outcome of the study. Nonetheless, Caso et al1 did pioneer the 
exploration of this important clinical question and was able to further the hypothesis that 
coenzyme Q10 depletion being linked to myopathic pain.  
Young et al17 admitted there may have only been a small increase in myalgia 
scores with either treatment regime, possibly because patients did not experience 
sufficiently severe myalgia to observe a benefit from coenzyme Q10 supplementation. 
This same defect may also be applied to Caso et al1 as they did not standardize pain 
severity. In Young et al17 patients were previously exposed to the intervention of 
coenzyme Q10, although a 2 week washout period of coenzyme Q10 was reported.  Pre-
exposure to the intervention may have skewed the outcome of the trial. Confounding 
these issues, patients were also able to discontinue or decrease statin supplementation 
based on their subjective myalgia symptoms, therefore, it is difficult to discern if the 
decrease in statin drug or the coenzyme Q10 supplementation decreased the myopathy. 
This study also had a small sample size. 
Langsjoen et al25 supported Caso et al1 in that it did find coenzyme Q10 
supplementation to have a positive outcome on statin myopathy. However, this study had 
an open design, therefore, there was unequivocal bias interpretation of the intervention by 
the study population or the results of the investigators. This study also had two 
interventions from the beginning of the trial, discontinuing statin drug therapy and the co-
administration of coenzyme Q10. Therefore, as with Young et al17, it is difficult to 
discern which of the two interventions might have had the positive effect on myalgia 
outcomes. There were also multiple confounding variables such as age, and disease states 
that were reported but not accounted for in the results of this study.  
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Future Avenues 
Based on the limited research presented here, additional studies are clearly 
warranted. Future research should follow the lead of Young et al17 and Caso et al1, with 
randomized control trials of patients with statin myopathy being treated with coenzyme 
Q10 and should improve on their foundation by recruiting larger number of participants. 
Molyneux et al26 is accurate in stating that adequately powered randomized controlled 
trials are now required to establish if there is a role for CoQ10 supplementation in the 
treatment of statin myopathy. These future studies should better their outcomes by 
continuing to eliminate confounding variables. Studies should be aimed at including 
subsets of the population on the same statin drug, dosage and length of use. Furthermore, 
the supplementation of CoQ10 formulation should be the same, secondary to the 
bioavailability of the various brands and formulation of CoQ10.27 Moreover, the results 
of these studies should be compared to the results of studies measuring the same variable 
but on different statin medications.  
A more clearly identified definition of myopathy by statin withdrawal and re-
challenge should be included in future studies. Simultaneously, a more objective pain 
scale to measure myopathic symptoms must be used to help standardize previous 
subjective measurements. Patients should then be compared to groups of patients with 
more severe levels of myalgia. There is also a need to develop studies that represent 
subgroups of statin-treated populations for whom Coenzyme Q10 supplementation may 
be more likely to produce a clinical benefit. The placebo benefit of coenzyme Q10 on 
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myopathic pain must also be accounted for. Finally, these studies must address and 
measure any adverse effects of supplementation with coenzyme Q10.  
 
CONCLUSION 
 Statins are efficacious lipid-lowering agents that are commonly use and 
considered safe. Statin medications are essential for the treatment of hypercholesterimia 
as well as for primary and secondary prevention of cardiovascular disease and have been 
shown to decrease morbidity and mortality in coronary events.2 In addition to their use in 
dyslipidemic disorders, the pleiotropic effects of statins have led to wider use in other 
disorders, such as cancer, stroke and inflammatory conditions.8 Therefore, the expanded 
use of statin medication demands awareness, recognition and proper evaluation and 
treatment of myalgia and myopathy by healthcare providers. The frequency of mild 
muscle-related symptoms in primary care can be under-estimated because physicians 
might overlook, and patients might fail to report, such symptoms, especially if they are 
not interfering with activities of daily living.28 Therefore, the health care provider-patient 
relationship must work collaboratively to decide how these statin-associated muscle 
symptoms can be managed so that the patient can maintain the appropriate statin 
treatment.   
Myopathy is one of the chief complaints patients have while taking statin 
medications. Strategies for managing statin intolerance are numerous. They include 
changing statins, intermittent dosing, increasing lifestyle modifications and using other 
LDL-C-lowering agents like bile acid sequestrants and ezetimibe.9 If myopathy can be 
treated with Coenzyme Q10 supplementation, the patient can maintain the appropriate 
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statin medication and continue to gain its benefits without experiencing the myopathy 
side effect of the drug. Moreover, if it is proven through further research that myopathic 
pain can be treated with adequate intake of Coenzyme Q10, this supplement may be used 
as a prophylactic to prevent myopathy. Despite research efforts, the role of coenzyme 
Q10 supplementation in the treatment of statin induced myalgia remains undetermined.  
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TABLES 
 
Table 1: Appraisal Criteria 
 
Criterion Caso et al. (2007) Young, BS et al. 
(2007) 
Langsjoen, P.H et al. 
(2005) 
Study Type 
+1: Randomized Control Trials; Prospective Cohort 
 
0: Retrospective or Case Study 
 
 
                 1 
 
 
                   1 
 
 
                  1 
Well Defined Inclusion Criteria 
+1: Pt on statin reporting myopathy  
 
0: Pt on statin with no reports of myopathy 
 
 
                 1 
 
 
                   1 
 
 
                  1 
Sample Size 
+1: >100 patients 
 
0:<100 patients 
 
 
                 0 
 
 
                   0 
 
 
                  0 
Control & Study Subjects Similar at 
Beginning of Study 
+1: Matched for age, sex, race 
 
0: Discrepancy of control vs study subjects OR no 
control comparison  
 
 
                 1 
 
 
                   1 
 
 
                  0 
Confounding Variables Reported and 
Explained 
+1: Diagnoses; dietary and lifestyle habits (i.e. 
smoking);  
 
0: Confounding Variable not explained 
 
 
 
                 1 
 
 
 
                   1 
 
 
 
                 1 
Subjects on Same Statin at Beginning of 
Study 
+1: Yes 
 
0: No 
 
 
                 0 
 
 
 
                   1 
 
 
                   0 
Subjects on Similar Doses of Statin at 
Beginning of Study 
+1: Yes 
 
0: No 
 
 
                 0 
 
 
                    1 
 
 
                   0 
Researcher Blinded to Control vs. Q10 
subjects 
+1: Yes 
 
0: No 
 
 
 
                 1 
 
 
                    1 
 
 
                  0 
Total                5/8                    7/8                   3/8 
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Table 2:  Matrix of Reviewed Literature  
 
Author/  Title/ 
Journal 
Population Intervention Comparison Outcome Validity 
Score 
Giuseppe Caso et al. 
(2007) 
Adult Pts. treated for HLD with 
HMG-CoA reductace inhibitor 
(statin) reporting myopathic 
symptoms 
Coenzyme Q10 Vitamin E (similar in 
appearance & 
antioxidative effect) 
-Myopathic Symptoms  
 
-Interferance with pts ADLs 
   5/8 
Young, BS et al. (2007) Adult Patients unable to continue 
taking adequate dose of Statin 
secondary to myopathic pain 
Coenzyme Q10 Placebo -# of patients who tolerated 
simvastatin  at therapeutic dose 
 
-# of patients who remained on 
simvastatin therapy 
 
-Change in Myalgia Score 
    7/8 
Langsjoen, P.H et al. 
(2005) 
Adult Statin Drug Users w/AE 
associated with Statin use 
D/C Statin & 
Begin Coenzyme 
Q10 
None -Myalgia 
 
-Fatigue 
 
-Dyspnea 
 
-Memory Loss 
 
-Peripheral Neuropathy 
     3/8 
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FIGURES 
 
Figure 1: The Cholesterol Biosynthetic Pathway 
 
 
 
 
 
 
 
 
 
 
 
This figure shows where statin medications work on the mevalonate pathway. It also 
depicts how both cholesterol and coenzyme Q10 are synthesized from the same pathway. 
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